Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2023 Results on March 27, 2024
Precision BioSciences Presents Preclinical Data Highlighting PBGENE-PMM as a Potential Therapy for Primary Mitochondrial Myopathy
Precision BioSciences Announces MHRA Approval for Partner iECURE
Precision Bio Announces $40.0 Million Offering of Common Stock and Warrants
Precision Bio Announces Proposed Public Offering of Common Stock and Warrants
Precision BioSciences Announces Proposed Public Offering of Common Stock
Precision Announces Non-Exclusive Patent License Agreement with Caribou
Precision BioSciences Receives Pre-IND Feedback from US FDA for PBGENE-HBV